AUTHOR=Wang Dongsheng , Fang Shihua , Hu Xiaowen , Xu Qixia , Chu Xinmin , Mei Xiaodong , Xie Wang 

TITLE=Metagenomic Next-Generation Sequencing Is Highly Efficient in Diagnosing Pneumocystis Jirovecii Pneumonia in the Immunocompromised Patients

JOURNAL=Frontiers in Microbiology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2022.913405

DOI=10.3389/fmicb.2022.913405

ISSN=1664-302X

ABSTRACT=<sec><title>Purposes</title><p>To explore the value of metagenomic next-generation sequencing (mNGS) in diagnosing pneumocystis jiroveciipneumonia (PJP) in the immunocompromised patients.</p></sec><sec><title>Methods</title><p>Data of 122 patients with PJP in an immunosuppressed state and 67 non-PJP patients were collected. The diagnostic efficacy of mNGS was compared with the conventional methods, including Gomori methenamine silver (GMS) staining and serum (1,3)-β-D-glucan (BDG). Changes of anti-microbial therapy for patients with PJP based on mNGS results were also reviewed.</p></sec><sec><title>Results</title><p>The diagnostic sensitivity of mNGS to PJP was higher than that of GMS and BDG (100% vs. 15 and 74.5%, <italic>p</italic> &lt; 0.001). The diagnostic specificity (91.%) was lower than that of GMS (100%), and similar with BDG (89.6%). In addition to P. jirovecii, mNGS revealed co-pathogens like human β-herpesvirus 5, human γ-pesvirus 4, and some other opportunistic pathogens. The reads of mNGS were remarkably higher in BALF than in blood samples. Initial antimicrobial treatment was modified in 89.3% patients based on the mNGS results, and 74 cases (60.7%) were treated with anti-<italic>P.</italic> jirovecii therapy.</p></sec><sec><title>Conclusion</title><p>mNGS is highly efficient in diagnosing PJP and good at identifying pathogens in mixed infections.</p></sec>